At the news
? NEUTRALIMPACT 5/10 8-K filed Mar 5, 2026 at 16:07 ET
Contineum Therapeutics reported Q4 2025 financial results showing a net loss of $15.2 million and research and development expenses of $12.8 million. The company raised $93 million in a public offering and increased its at-the-market (ATM) equity offering capacity from $75 million to $100 million. They initiated patient dosing in a Phase 2 trial for IPF and expect topline data from a chronic pain trial in Q2 2026. With $262.9 million in cash, they project runway into mid-2029.
- Net loss of $15.2 million for Q4 2025, compared to $14.6 million in Q4 2024
- Cash, cash equivalents, and marketable securities totaled $262.9 million as of December 31, 2025
- Completed public offering generating $93 million in net proceeds
- Increased ATM equity offering capacity from $75 million to $100 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access